MarginsXMarginsX
Home › Markets › Health Care › TNGX

Tango Therapeutics Inc. (TNGX)

TNGX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$24.17
-5.22% on the day
Market cap
$4.1B
Mid cap
Revenue · 2025
$62.4M
+48.3% on 2024
Net income · 2025
-$101.6M
-162.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/0001193125-26-092518-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTNGX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001819133
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$62.4M
Net income-$101.6M
Operating income-$111.3M
Net margin-162.9%
Operating margin-178.4%
Revenue growth+48.3%
Cash$112.3M
Total assets$398.7M
P/E (computed)Net income was not positive
P/S (computed)65.7×

Warning signs

Cash runway
6.9 months
$86.8M cash at September 30, 2026
Share count, 1 year
+25.9%
2025-10-28 to 2026-11-02 · +91.5% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$11.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$86.8M cash; operating cash flow -$37.5M a quarter.Report 2026-09-30
Shares outstanding169,455,160 (2026-11-02); 134,593,998 a year earlier; 88,467,269 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-08-11
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $11.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$68.4M-$37.1M$86.8MNo debt tags$010-Q 2026-11-09
Q2 2026
2026-06-30
$0-$55.3M-$38.9M$345.6MNo debt tags$53.8M10-Q 2026-08-11
Q1 2026
2026-03-31
$0-$45.5M-$44.4M$157.8MNo debt tags$57.0M10-Q 2026-05-13
Q4 2025
2025-12-31
$0-$38.7M-$29.7M$112.3MNo debt tags$62.4M10-K 2026-03-05
Q3 2025
2025-09-30
$53.8M$15.9M-$31.0M$58.3MNo debt tags$66.5M10-Q 2026-11-09
Q2 2025
2025-06-30
$3.2M-$38.9M-$36.5M$58.3MNo debt tags$24.3M10-Q 2026-08-11
Q1 2025
2025-03-31
$5.4M-$39.9M-$41.7M$58.4MNo debt tags$41.0M10-Q 2026-05-13
Q4 2024
2024-12-31
$4.1M-$37.7M-$36.6M$69.5MNo debt tags$42.1M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-11
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-17

Source: SEC EDGAR submissions feed, 430 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+18.6%
1 month+14.8%
3 months-0.6%
Year to date+187.8%
1 year+230.3%
From 52-week high-22.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
XENEXenon Pharmaceuticals Inc. Common Shares$39.26-3.01%$3.9B
OGNOrganon & Co. Common Stock$13.900.00%$3.7B
ABCLAbCellera Biologics Inc. Common Shares$11.12-3.22%$3.6B
IONSIonis Pharmaceuticals Inc.$28.01-3.61%$4.7B
AMLXAmylyx Pharmaceuticals Inc.$27.80-8.22%$3.6B
PBLSParabilis Medicines Inc.$28.45+0.07%$3.5B
TVTXTravere Therapeutics Inc.$49.70-1.88%$4.8B
COGTCogent Biosciences Inc.$27.44-3.92%$4.8B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier